Sustained Response to Vemurafenib in an BRAF V600E-mutated Anaplastic Thyroid Carcinoma Patient.

Sustained Response to Vemurafenib in an BRAF V600E-mutated Anaplastic Thyroid Carcinoma Patient.

Thyroid. 2016 Aug 17;

Authors: Prager G, Koperek O, Mayerhöfer M, Muellauer L, Wrba F, Niederle B, Zielinski C, Raderer M

Abstract
Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited therapeutic options. Although rare, the prognosis of locally advanced or metastasized diseases is poor with a one year survival rate of in the range of 8 - 20%(1). Albeit aggressive multimodal approaches including surgery, radiation and chemotherapy are applied, the toxicities are mostly profound with a still dismal outcome. In view of the minimal efficacy of conventional chemotherapies and an unmet clinical need, a detailed definition of the molecular driver mutations of an individual tumor might thus improve patient selection and provide a rationale for personalized treatment design. In this context, possible somatic mutations of driver molecules such as BRAF, Alk, PIK3CA and others were suggested as potential druggable targets. Here, we present the case of an 80 year-old female patient with BRAF V600E mutation-bearing ATC and an excellent and sustained response to single agent vemurafenib.

PMID: 27532222 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2bvaW3H
via IFTTT